Cargando…

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis

More clinical evidence is needed regarding the relative priority of treatments for brain metastases (BMs) from EGFR/ALK-negative/unselected non-small cell lung cancer (NSCLC). PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov databases were searched. Overall survival (OS), cen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chengkai, Zhou, Wenjianlong, Zhang, Dainan, Ma, Shunchang, Wang, Xi, Jia, Wang, Guan, Xiudong, Qian, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938645/ https://www.ncbi.nlm.nih.gov/pubmed/36820064 http://dx.doi.org/10.1515/med-2022-0574

Ejemplares similares

Surgical Experience of Transcranial Approaches to Large-to-Giant Pituitary Adenomas in Knosp Grade 4
por: Guan, Xiudong, et al.
Publicado: (2022)

MicroRNA-935 Directly Targets FZD6 to Inhibit the Proliferation of Human Glioblastoma and Correlate to Glioma Malignancy and Prognosis
por: Zhang, Dainan, et al.
Publicado: (2021)

Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor
por: Wang, Xi, et al.
Publicado: (2023)

Identification of a Glycolysis-Related LncRNA Signature to Predict Survival in Diffuse Glioma Patients
por: Wang, Yangyang, et al.
Publicado: (2021)

CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment
por: Guan, Xiudong, et al.
Publicado: (2021)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
por: Wang, Huijuan, et al.
Publicado: (2019)

Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms
por: Griesinger, Frank, et al.
Publicado: (2018)

Consistency of pituitary adenomas: Amounts of collagen types I and III and the predictive value of T2WI MRI
por: Li, Peiliang, et al.
Publicado: (2021)

Preclinical assessment of IRDye800CW‐labeled gastrin‐releasing peptide receptor‐targeting peptide for near infrared‐II imaging of brain malignancies
por: Zhang, Yuan, et al.
Publicado: (2023)

Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases
por: Ying, Xiaofang, et al.
Publicado: (2020)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
por: Ferreira, Daniela, et al.
Publicado: (2021)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022)

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
por: Qiao, Meng, et al.
Publicado: (2020)

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
por: Tan, Xueyun, et al.
Publicado: (2022)

Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies
por: Petrelli, Fausto, et al.
Publicado: (2018)

LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases: An Observational Study
por: Hu, Nan, et al.
Publicado: (2015)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Therapeutic Sequencing in ALK(+) NSCLC
por: Elsayed, Mei, et al.
Publicado: (2021)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Differences of macrophages in the tumor microenvironment as an underlying key factor in glioma patients
por: Wang, Yangyang, et al.
Publicado: (2022)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas
por: Dai, Zunyan, et al.
Publicado: (2012)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases
por: Wang, Yu, et al.
Publicado: (2023)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

CPNE3 regulates the cell proliferation and apoptosis in human Glioblastoma via the activation of PI3K/AKT signaling pathway
por: Zhang, Dainan, et al.
Publicado: (2021)

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
por: Xiao, Juanjuan, et al.
Publicado: (2022)

Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
por: Liang, Wenhua, et al.
Publicado: (2016)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis
por: Wu, Min, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4h9osd54ikiqao9k7h4shvies0